FarmaKology Newsletter - Issue #29
Discover more from FarmaKology’s Substack
FarmaKology Newsletter - Issue #29
Today's Startup
Bluedrop Medical
Bluedrop Medical are developing a system to reduce the burden of diabetic foot ulcers.There are currently almost half a billion diabetics worldwide and it has been estimated that up to 25% will develop a foot ulcer at some point in their life. Of the millions who develop ulcers worldwide every year, hundreds of thousands will require amputation due to infection. Bluedrop Medical are combining detection technology with the internet of things, to create a connected health system capable of identifying ulcers early, where they can be treated more effectively and cheaply.
News
The Wistar Institute joins global effort to create coronavirus vaccine
With 11 coronavirus cases confirmed in the United States, the Wistar Institute is among the leading laboratories working to develop a vaccine for the virus.The Wistar Institute announced its partnership with Inovio Pharmaceuticals to accelerate vaccine development for the recent coronavirus outbreak.
Clovis Oncology Announces Availability And Reimbursement For Rubraca® (Rucaparib) Tablets For Women With Relapsed Ovarian Cancer In France
Clovis Oncology, Inc. today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.
RegeneRx Partner Updates on Phase 3 Dry Eye Trial
RegeneRx Biopharmaceuticals, Inc. , a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that GtreeBNT, its Korean partner in the U.S. for development of RGN-259 for the treatment of dry eye disease, issued an update on the U.S. phase 3 clinical trial.
LIGAND'S TECHNOLOGIES SUPPORT AND ENABLE POTENTIAL CORONAVIRUS TREATMENTS
Ligand Pharmaceuticals Incorporated announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China. Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligand’s Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms.
Research & Study
Alarmingly high rate of antibiotics prescribed without evidence of office visit
HIV antibody therapy is associated with enhanced immune responses in infected individuals
New type of immunotherapy may better treat melanoma
Podcast
Job Opportunities
Medical Representative
Pharmacy Technician
clinical pharmacist
Pharmacist
Upcoming Events
11th Annual SCOPE Summit, Summit for Clinical Ops Executives
EAEU & CIS Pharmaceutical Forum 2020
Pharmapack 2020
Video
